Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled ZYESAMI for Severe COVID-19
NCT04360096Phase 3Terminated
- Sponsor
- APR Applied Pharma Research
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of aviptadil in coronavirus disease 2019 (COVID-19), sponsored by APR Applied Pharma Research. Started Feb 2021; status: terminated.
02
Drugs
aviptadil
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04360096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360096.